Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6174-6177

  Chauhan, Dharminder ^a   Li, Guilan ^a   Shringarpure, Reshma ^a   Podar, Klaus ^a   Ohtake, Yasuyuki ^b   Hideshima, Teru ^a   Anderson, Kenneth C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ASAHI BREWERIES LTD   (Japan)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; COMPLEMENTARY DNA; HEAT SHOCK PROTEIN 27; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DRUG RESISTANCE, NEOPLASM; HEAT-SHOCK PROTEINS; HUMANS; LEUPEPTINS; LYMPHOMA; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, MESSENGER; TRANSFECTION;

EID: 0141953292     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Goldberg, A. L., and Rock, K. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat. Med., 8: 338-340, 2002.
2. Adams, J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov. Today, 8: 307-315, 2003.
3. Orlowski, R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ., 6: 303-313, 1999.
4. Teicher, B. A., Ara, G., Herbst, R., Palonmbella, V. J., and Adams, J. The Proteosome inhibitor PS-341 in cancer therapy. Clin. Cancer Res., 5: 2638-2645, 1999.
5. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Schlossman, R., Munshi, N. C., Hideshima, T., and Anderson, K. C. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101: 2377-2380, 2003.
6. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 348: 2609-2617, 2003.
7. Gavioli, R., Frisan, T., Vertuani, S., Bornkamm, G. W., and Masucci, M. G. c-myc oveoxpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat. Cell Biol., 3: 283-288, 2001.
8. Cory, S., and Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2: 647-656, 2002.
9. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libennann, T. A., Treon, S. P., Munshi, N. C., Richardson, P. G., Hideshima, T., and Anderson, K. C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA, 99: 14374-14379, 2002.
10. Paul, C., Manero, F., Gonin, S., Kretz-Remy, C., Virot, S., and Arrigo, A. P. Hsp27 as a negative regulator of cytochrome C release. Mol. Cell. Biol., 22: 816-834, 2002.
11. Concannon, C. G., Gorman, A. M., and Samali, A. On the role of Hsp27 in regulating apoptosis. Apoptosis, 8: 61-70, 2003.
12. Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Catley, L., Tai, Y. T., Hayashi, T., and Shringarbure, R. Hsp27 inhibits the release of mitochondrial protein Smac and confers Dexamthasone Resistance in multiple myeloma cells. Blood, in press, 2003.
13. Chauhan, D., Catley, L., Hideshima, T., Li, G., Leblanc, R., Gupta, D., Sattler, M., Richardson, P., Schlossman, R. L., Podar, K., Weller, E., Munshi, N., and Anderson, K. C. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood, 100: 2187-2194, 2002.
14. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Krett, N., Halgren, R., Rosen, S., Kufe, D., Kharbanda, S., and Anderson, K. C. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells. J. Biol. Chem., 272: 29995-29997, 1997.
15. Chauhan, D., Li, G., Auclair, D., Hideshima, T., Richardson, P., Podar, K., Mitsiades, N., Mitsiades, C., Li, C., Kim, R. S., Munshi, N., Chen, L. B., Wong, W., and Anderson, K. C. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood, 101: 3606-3614, 2003.
16. Li, C., and Wong, W. H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA, 98: 31-36, 2001.
17. Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K., and Ohtake, Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett., 168: 173-181, 2001.
18. Reinheckel, T., Sitte, N., Ullrich, O., Kuckelkorn, U., Davies, K. J., and Grune, T. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem. J., 335 (Pt 3): 637-642, 1998.
19. Oberhammer, F. A., Hochegger, K., Froschl, G., Tiefenbacher, R., and Pavelka, M. Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase. J. Cell Biol., 126: 827-837, 1994.
20. Zimmermann, J., Erdmann, D., Lalande, I., Grossenbacher, R., Noorani, M., and Furst, P. Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MADI. Oncogene, 19: 2913-2920, 2000.